Britain approves Novavax COVID-19 vaccine Nuvaxovid for children aged between 12 and 17 years

London: The United Kingdom on Friday approved Novavax's COVID-19 vaccine for children aged between 12 and 17 years. Notably, the Medicines and Healthcare products Regulatory Agency (MHRA) also cleared mRNA vaccines made by Moderna and Pfizer-BioNTech for this age group, reported Reuters.

"Nuvaxovid, the COVID-19 vaccine developed by Novavax, has today been granted an extension to its existing UK approval, for 12- to 17-year-olds. This extension has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA)," wrote, gov.uk, the website owned by the HM government.

Notably, the Conditional Marketing Authorisation (CMA) extension granted by the MHRA is valid in the UK only. It was approved via the European Commission (EC) Decision Reliance Route.